<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8114">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00856635</url>
  </required_header>
  <id_info>
    <org_study_id>PM030</org_study_id>
    <nct_id>NCT00856635</nct_id>
  </id_info>
  <brief_title>A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Glatiramer Acetate (GA) on the Retinal Nerve Fiber Layer (RNFL) and Visual Function in Patients With a First Episode of Acute Optic Neuritis (AON). (Octagon)</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Multicenter Study of the Effects of Glatiramer Acetate (GA) on the Retinal Nerve Fiber Layer (RNFL) and Visual Function in Patients With a First Episode of Acute Optic Neuritis (AON)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Pharmaceutical Industries</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of the study is to determine whether glatiramer acetate 20 mg once daily
      reduces the amount of axonal loss in the optic nerve after a first event of acute optic
      neuritis compared to placebo patients and to generate data supporting the potential
      neuroprotective effect of glatiramer acetate in a human in vivo model of axonal loss.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2009</start_date>
  <completion_date type="Actual">February 2011</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Retinal Nerve Fiber Layer Thickness at Baseline and Month 6</measure>
    <time_frame>Baseline and Month 6</time_frame>
    <safety_issue>No</safety_issue>
    <description>Axonal loss in the optic nerve (due to optic neuritis) was assessed by measuring retinal nerve fiber thickness of the affected eye using optical coherence tomography (OCT) at Baseline and Month 6.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To Evaluate Changes on Additional OCT Parameters and Other Visual Function and Clinical Parameters.</measure>
    <time_frame>6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Optic Neuritis</condition>
  <arm_group>
    <arm_group_label>Glatiramer acetate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received glatiramer acetate 20 mg subcutaneous injection once a day for up to 6 months.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received placebo subcutaneous injection once a day for up to 6 months.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glatiramer Acetate</intervention_name>
    <description>20 mg injected daily subcutaneously</description>
    <arm_group_label>Glatiramer acetate</arm_group_label>
    <other_name>Copaxone</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>injected daily subcutaneously</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age: 18 - 45 years

          -  Isolated, unilateral, first acute optic neuritis (AON) event consistent with
             inflammatory demyelinization, not explained by other etiologies. Onset of AON is
             defined by the presentation of visual disturbances.

          -  Able to provide written informed consent prior to enrollment

          -  Willing and able to comply with the protocol requirements for the duration of the
             study

          -  For women of child bearing potential:

               -  A negative urine pregnancy test o

               -  Willing to practice an acceptable method of birth control •

          -  Willing to receive a steroidal regimen

        Exclusion Criteria:

          -  A diagnosis of clinically definite multiple sclerosis (MS) (Clinically Definite
             Multiple Sclerosis)

          -  Current use of any approved disease modifying agents for treatment of MS

          -  Prior clinical episode of optic neuritis in either eye

          -  Bilateral AON

          -  Inability to undergo study evaluations in both eyes

          -  Known ocular or neurological conditions or abnormalities other than refractive error
             that impair visual function

          -  Retrogeniculate visual loss

          -  Refractive error of greater than +6 or -6 diopters

          -  Neuromyelitis Optica (Devic's disease)

          -  Systemic diseases that cause inflammatory optic neuropathy, including but not limited
             to Sarcoidosis, Systemic lupus erythematosus (SLE), Wegener's Granulomatosis,
             Syphilis, human immunodeficiency virus (HIV)

          -  Known ocular conditions that preclude dilation

          -  Any condition that may interfere with performance of Optical Coherence Tomography
             (OCT): corneal, lens or fundoscopic abnormality, a co-morbid ocular condition not
             related to optic neuritis as detected on the OCT reading

          -  Any condition that precludes administration of Glatiramer Acetate, such as a known
             history of sensitivity to mannitol

          -  Diabetes Mellitus Types I or II

          -  Gastric bypass surgery

          -  Current use of chemotherapy or radiotherapy

          -  Treatments that may cause visual loss such as plaquenil, anti-tubercular agents,
             interferon (IFN)-alpha therapy, monoclonal antibodies Cardiac medications that may
             affect visual evaluations such as digitalis, amiodarone, quinine

          -  Ongoing treatment with steroids (for longer than 10 days) within the last 3 months

          -  Significant or unstable medical, systemic, psychiatric or logistical condition that
             affects the patient's ability to give informed consent or to complete the study
             procedures

          -  Use of an investigational drug within 30 days prior to randomization
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark J. Kupersmith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Roosevelt Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Peter Calabresi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>John Hopkins School of Medicine</affiliation>
  </overall_official>
  <removed_countries>
    <country>United States</country>
  </removed_countries>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 20, 2013</lastchanged_date>
  <firstreceived_date>March 4, 2009</firstreceived_date>
  <firstreceived_results_date>July 11, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neuritis</mesh_term>
    <mesh_term>Optic Neuritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Copolymer 1</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Glatiramer Acetate</title>
          <description>Participants received glatiramer acetate 20 mg subcutaneous injection once a day for up to 6 months.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Participants received placebo subcutaneous injection once a day for up to 6 months.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Study Drug</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Pregnancy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Serious Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Discontinued at Randomization</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The safety analysis set included all patients who had been randomized to the study and received at least one dose of study drug.</population>
      <group_list>
        <group group_id="B1">
          <title>Glatiramer Acetate</title>
          <description>Participants received glatiramer acetate 20 mg subcutaneous injection once a day for up to 6 months.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Participants received placebo subcutaneous injection once a day for up to 6 months.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="20"/>
                <measurement group_id="B2" value="20"/>
                <measurement group_id="B3" value="40"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="31.7" spread="7.1"/>
                <measurement group_id="B2" value="34.4" spread="6.5"/>
                <measurement group_id="B3" value="33.0" spread="6.9"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="13"/>
                <measurement group_id="B2" value="15"/>
                <measurement group_id="B3" value="28"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="7"/>
                <measurement group_id="B2" value="5"/>
                <measurement group_id="B3" value="12"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Asian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="2"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="2"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Caucasian</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="13"/>
                <measurement group_id="B2" value="15"/>
                <measurement group_id="B3" value="28"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Black/African American</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="3"/>
                <measurement group_id="B3" value="4"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Hispanic</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="4"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Other</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="1"/>
                <measurement group_id="B2" value="1"/>
                <measurement group_id="B3" value="2"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Retinal Nerve Fiber Layer Thickness at Baseline and Month 6</title>
        <description>Axonal loss in the optic nerve (due to optic neuritis) was assessed by measuring retinal nerve fiber thickness of the affected eye using optical coherence tomography (OCT) at Baseline and Month 6.</description>
        <time_frame>Baseline and Month 6</time_frame>
        <safety_issue>No</safety_issue>
        <population>The modified ITT intent-to-treat (mITT) analysis set included all patients who had been randomized to the study, received at least one dose of study drug, had a baseline OCT evaluation, and had at least one non-missing post-baseline OCT evaluation.</population>
        <group_list>
          <group group_id="O1">
            <title>Glatiramer Acetate</title>
            <description>Participants received glatiramer acetate 20 mg subcutaneous injection once a day for up to 6 months.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Participants received placebo subcutaneous injection once a day for up to 6 months.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="18"/>
                  <measurement group_id="O2" value="18"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Retinal Nerve Fiber Layer Thickness at Baseline and Month 6</title>
            <description>Axonal loss in the optic nerve (due to optic neuritis) was assessed by measuring retinal nerve fiber thickness of the affected eye using optical coherence tomography (OCT) at Baseline and Month 6.</description>
            <units>µm</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Baseline (n=18, 18)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="128.1" spread="11.9"/>
                  <measurement group_id="O2" value="130.5" spread="8.9"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Month 6 (n=13, 13)</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="89.5" spread="8.9"/>
                  <measurement group_id="O2" value="88.0" spread="5.5"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>To Evaluate Changes on Additional OCT Parameters and Other Visual Function and Clinical Parameters.</title>
        <time_frame>6 months</time_frame>
        <safety_issue>Yes</safety_issue>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Glatiramer Acetate</title>
          <description>Participants received glatiramer acetate 20 mg subcutaneous injection once a day for up to 6 months.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Participants received placebo subcutaneous injection once a day for up to 6 months.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Sponsor has the right 60 days before submission for publication to review/provide comments. If the Sponsor’s review shows that potentially patentable subject matter would be disclosed, publication or public disclosure shall be delayed for up to 90 additional days in order for the Sponsor, or Sponsor’s designees, to file the necessary patent applications. In multicenter trials, each PI will postpone single center publications until after disclosure or publication of multicenter data.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Scott Kolodny, M.D.</name_or_title>
      <organization>Teva Pharmaceuticals, Medical Affairs</organization>
      <phone>440-327-1811</phone>
      <email>scott.kolodny@tevapharm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
